Literature DB >> 16223825

Disappointing biotech.

Roberta Joppi1, Vittorio Bertele', Silvio Garattini.   

Abstract

Mesh：

Year:  2005        PMID： 16223825      PMCID： PMC1255805          DOI： 10.1136/bmj.331.7521.895

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

1.  Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors:  U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study.

Authors:  M Uppenkamp; A Engert; V Diehl; D Bunjes; D Huhn; G Brittinger
Journal:  Ann Hematol       Date:  2001-12-14       Impact factor: 3.673

4.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Authors:  F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

Review 5.  Are me-too drugs justified?

Authors:  S Garattini
Journal:  J Nephrol       Date:  1997 Nov-Dec       Impact factor: 3.902

6.  A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Authors:  S C Goldman; J S Holcenberg; J Z Finklestein; R Hutchinson; S Kreissman; F L Johnson; C Tou; E Harvey; E Morris; M S Cairo
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 7.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 8.  Clinical cardiac tolerability of trastuzumab.

Authors:  Edith A Perez; Richard Rodeheffer
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

9.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

Authors:  B Nashan; R Moore; P Amlot; A G Schmidt; K Abeywickrama; J P Soulillou
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321

10.  Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

Authors:  B I Eriksson; S Ekman; P Kalebo; B Zachrisson; D Bach; P Close
Journal:  Lancet       Date:  1996-03-09       Impact factor: 79.321
View more
  10 in total

1.  EMA's reflection on placebo does not reflect patients' interests.

Authors:  Vittorio Bertele'; Rita Banzi; Christian Gluud; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2011-12-02       Impact factor: 2.953

2.  Disappointing article, not disappointing biotech.

Authors:  Fredric J Cohen
Journal:  BMJ       Date:  2005-10-29

3.  Should we really worry about "launch delays" of new drugs in OECD countries?

Authors:  Livio Garattini; Simone Ghislandi
Journal:  Eur J Health Econ       Date:  2007-03

4.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 5.  Do we learn the right things from clinical trials?

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  Eur J Clin Pharmacol       Date:  2008-01-29       Impact factor: 2.953

6.  The Italian Horizon Scanning Project.

Authors:  Roberta Joppi; Luca Demattè; Anna Michela Menti; Daniela Pase; Chiara Poggiani; Luigi Mezzalira
Journal:  Eur J Clin Pharmacol       Date:  2009-06-03       Impact factor: 2.953

Review 7.  Literature review on the structure and operation of Pharmacy and Therapeutics Committees.

Authors:  Esther Durán-García; Bernardo Santos-Ramos; Francesc Puigventos-Latorre; Ana Ortega
Journal:  Int J Clin Pharm       Date:  2011-03-18

8.  Toward a definition of pharmaceutical innovation.

Authors:  Steven Morgan; Ruth Lopert; Devon Greyson
Journal:  Open Med       Date:  2008-01-30

9.  How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.

Authors:  Derek J Ward; Angharad Slade; Tracey Genus; Orsolina I Martino; Andrew J Stevens
Journal:  BMJ Open       Date:  2014-10-24       Impact factor: 2.692

10.  Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents.

Authors:  Joseph D Mosca; Yung-Nien Chang; Gregory Williams
Journal:  Retrovirology       Date:  2007-05-15       Impact factor: 4.602
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.